A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).

被引：0
|
作者：
Schlumberger, Martin
Jarzab, Barbara
Cabanillas, Maria E.
Robinson, Bruce
Pacini, Furio
Ball, Douglas Wilmot
McCaffrey, Judith C.
Newbold, Kate
Allison, Roger
Martins, Renato
Licitra, Lisa F.
Shah, Manisha H.
Bodenner, Donald
Elisei, Rossella
Burmeister, Lynn A.
Funahashi, Yasuhiro
Sellecchia, Rita
Andresen, Corina
O'Brien, James P.
Sherman, Steven I.
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Maria Sklodowska Curie Mem Canc Ctr, Gliwice, Poland
[3] Inst Oncol, Gliwice, Poland
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Royal N Shore Hosp, St Leonards, NSW 2065, Australia
[6] Azienda Osped Univ Senese, Siena, Italy
[7] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[8] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[9] Royal Marsden Hosp, Sutton, Surrey, England
[10] Royal Brisbane & Womens Hosp, Herston, Qld, Australia
[11] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[12] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[13] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA
[14] Ohio State Univ, Ctr Comprehens Canc, Solove Res Inst, Columbus, OH 43210 USA
[15] Univ Arkansas, Little Rock, AR 72204 USA
[16] Univ Pisa, Pisa, Italy
[17] Univ Minnesota, Minneapolis, MN USA
[18] Eisai, Andover, MA USA
[19] European Knowledge Ctr, Hatfield, Herts, England
[20] Eisai, Woodcliff Lake, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5591
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
    Schlumberger, Martin
    Jarzab, Barbara
    Cabanillas, Maria E.
    Robinson, Bruce
    Pacini, Furio
    Ball, Douglas W.
    McCaffrey, Judith
    Newbold, Kate
    Allison, Roger
    Martins, Renato G.
    Licitra, Lisa F.
    Shah, Manisha H.
    Bodenner, Donald
    Elisei, Rossella
    Burmeister, Lynn
    Funahashi, Yasuhiro
    Ren, Min
    O'Brien, James P.
    Sherman, Steven I.
    CLINICAL CANCER RESEARCH, 2016, 22 (01) : 44 - 53
  • [2] A PHASE II TRIAL OF THE MULTI-TARGETED KINASE INHIBITOR LENVATINIB (E7080) IN ADVANCED MEDULLARY THYROID CANCER (MTC)
    Schlumberger, M.
    Jarzab, B.
    Cabanillas, M. E.
    Robinson, B.
    Furio, P.
    Ball, D. W.
    McCaffrey, J. C.
    Newbold, K.
    Allison, R.
    Martins, R. G.
    Licitra, L.
    Shah, M. H.
    Bodenner, D. L.
    Elisei, R.
    Burmeister, L. A.
    Funahashi, Y.
    Sellecchia, R.
    Andresen, C.
    O'Brien, J. P.
    Sherman, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 35 - 36
  • [3] A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
    Sherman, S. I.
    Jarzab, B.
    Cabanillas, M. E.
    Licitra, L. F.
    Pacini, F.
    Martins, R.
    Robinson, B.
    Ball, D.
    McCaffrey, J.
    Shah, M. H.
    Bodenner, D.
    Allison, R.
    Newbold, K.
    Elisei, R.
    O'Brien, J. P.
    Schlumberger, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Phase I/II study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results
    Mitsunaga, Shuichi
    Ikeda, Masafumi
    Ueno, Hideki
    Nakachi, Kohei
    Morizane, Chigusa
    Kondo, Shunsuke
    Shimizu, Satoshi
    Kojima, Yasushi
    Suzuki, Takuya
    Tamai, Toshiyuki
    O'Brien, James P.
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [5] A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
    Boss, D. S.
    Glen, H.
    Beijnen, J. H.
    Keesen, M.
    Morrison, R.
    Tait, B.
    Copalu, W.
    Mazur, A.
    Wanders, J.
    O'Brien, J. P.
    Schellens, J. H. M.
    Evans, T. R. J.
    BRITISH JOURNAL OF CANCER, 2012, 106 (10) : 1598 - 1604
  • [6] A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
    D S Boss
    H Glen
    J H Beijnen
    M Keesen
    R Morrison
    B Tait
    W Copalu
    A Mazur
    J Wanders
    J P O'Brien
    J H M Schellens
    T R J Evans
    British Journal of Cancer, 2012, 106 : 1598 - 1604
  • [7] A PHASE IB CLINICAL TRIAL OF THE MULTITARGETED KINASE INHIBITOR LENVATINIB (E7080) IN COMBINATION WITH EVEROLIMUS FOR TREATMENT OF METASTATIC RENAL CELL CARCINOMA (RCC)
    Molina, A. M.
    Hutson, T. E.
    Larkin, J.
    Gold, A.
    Andresen, C.
    Wood, K.
    Motzer, R. J.
    Michaelson, M. D.
    ANNALS OF ONCOLOGY, 2012, 23 : 269 - 269
  • [8] A phase Ib clinical trial of the multitargeted kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
    Molina, Ana M.
    Hutson, Thomas E.
    Larkin, James M. G.
    Gold, Anne
    Andresen, Corina
    Wood, Karen
    Motzer, Robert John
    Michaelson, M. Dror
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [9] A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
    Chen, Jiaying
    Ji, Qinghai
    Cao, Junning
    Ji, Dongmei
    Bai, Chunmei
    Lin, Yansong
    Pan, Bin
    Sun, Guofang
    Li, Jing
    Qi, Chuan
    Hua, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Subgroup analyses of a phase 1/2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Ikeda, Masafumi
    Ikeda, Kenji
    Kudo, Masatoshi
    Osaki, Yukio
    Okusaka, Takuji
    Tamai, Toshiyuki
    Suzuki, Takuya
    Hisai, Takashi
    Miyagishi, Hideaki
    Okita, Kiwamu
    Kumada, Hiromitsu
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345